Ghislaine Gilleron

MiddleNext operates as an independent business association, that provides representation of listed companies. It engages, with its members, in dialogue and lobbying to decision-makers, economic stakeholders, and financial institutions. The company was founded in 1987 and is headquartered in Paris, France.

ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France.